Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Symproic® approved by FDA

    by
    • Optum Workers' Comp
    | Mar 28, 2017
    Tag Icon
    Opioids
    The U.S. Food and Drug Administration (FDA) has approved a new oral medication for the treatment of opioid-induced constipation (OIC). Symproic® (naldemedine) is an opioid antagonist indicated to treat OIC in adult patients with chronic non-cancer pain.


  • Addressing opioid analgesic use in workers' comp and auto no-fault

    by
    • Optum Workers' Comp
    | Mar 20, 2017
    Tag Icon
    Workers' Compensation, Opioids
    We are pleased to release our latest insight on addresing opioid analgesic use in workers' comp and auto no-fault. Inside you will find statistical trends impacting opioid analgesics today and our perspective on opioid analgesic use.


  • March 2017 Pharmacy Resource Guide now available

    by
    • Optum Workers' Comp
    | Mar 02, 2017
    Tag Icon
    Workers' Compensation, Pharmacy Fee Schedules
    We are pleased to share our March 2017 Pharmacy Resource Guide. Inside you will find a state-by-state guide to the pharmacy fee schedule and jurisdictional maps highlighting key workers’ compensation laws and regulations.


  • Naloxone - Take Home Products Offer New Doses

    by
    • Optum Workers' Comp
    | Jan 27, 2017
    Tag Icon
    Naloxone, FDA, Overdose, Opioids
    Two major pharmaceutical manufacturers have been approved by the United States Food and Drug Administration (FDA) to market new strengths of their naloxone products. Narcan® Nasal Spray and Evzio® auto-injector are indicated for the emergency treatment of opioid overdose, as manifested by respiratory and/or central nervous system depression.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.